00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2016-03-31 09:27:172016-03-31 09:27:17Mission Therapeutics to Present at Conferences in March – April 2016
00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2016-03-01 10:17:472016-03-01 10:17:47Mission Therapeutics to Present at Conferences in March 2016
00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2016-02-02 08:18:472016-02-02 08:18:47MISSION Therapeutics Raises £60 million to Progress Development of Novel DUB Inhibitors from Innovative Drug Platform
00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2015-09-22 14:02:402015-09-22 14:02:40MISSION Therapeutics receives funding from Innovate UK for DUB cancer programme
00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2015-09-01 09:00:252015-09-01 09:00:25MISSION Therapeutics appoints Michael Koslowski as Chief Medical Officer
